Koninklijke Philips Research and Development Expenses 2010-2022 | PHG

Koninklijke Philips annual/quarterly research and development expenses history and growth rate from 2010 to 2022. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Koninklijke Philips research and development expenses for the quarter ending September 30, 2022 were $0.619B, a 24.4% increase year-over-year.
  • Koninklijke Philips research and development expenses for the twelve months ending September 30, 2022 were $2.208B, a 7.9% increase year-over-year.
  • Koninklijke Philips annual research and development expenses for 2022 were $2.216B, a 3.7% increase from 2021.
  • Koninklijke Philips annual research and development expenses for 2021 were $2.137B, a 2.32% decline from 2020.
  • Koninklijke Philips annual research and development expenses for 2020 were $2.188B, a 3.67% increase from 2019.
Koninklijke Philips Annual Research and Development Expenses
(Millions of US $)
2022 $2,216
2021 $2,137
2020 $2,188
2019 $2,110
2018 $2,077
2017 $1,994
2016 $2,236
2015 $2,140
2014 $2,173
2013 $2,302
2012 $2,328
2011 $2,242
2010 $2,093
2009 $2,275
Koninklijke Philips Quarterly Research and Development Expenses
(Millions of US $)
2022-09-30 $619
2022-06-30 $521
2021-06-30 $566
2020-06-30 $501
2019-06-30 $498
2018-06-30 $507
2017-06-30 $463
2016-12-31 $579
2016-09-30 $573
2016-06-30 $566
2016-03-31 $519
2015-12-31 $589
2015-09-30 $524
2015-06-30 $534
2015-03-31 $492
2014-12-31 $485
2014-09-30 $528
2014-06-30 $584
2014-03-31 $576
2013-12-31 $620
2013-09-30 $579
2013-06-30 $543
2013-03-31 $560
2012-12-31 $634
2012-09-30 $552
2012-06-30 $562
2012-03-31 $581
2011-12-31 $609
2011-09-30 $551
2011-06-30 $548
2011-03-31 $535
2010-12-31 $560
2010-09-30 $506
2010-06-30 $508
2010-03-31 $520
2009-12-31 $643
2009-09-30 $532
2009-06-30 $571
2009-03-31 $530
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $15.021B $18.786B
Koninklijke Philips N.V. is the parent company of the Philips Group. The company realigned its three reporting operations into Diagnosis & Treatment businesses consists of Diagnostic Imaging, Ultrasound, Image-Guided Therapy and Enterprise Diagnostic Informatics businesses. Connected Care business comprises the Monitoring & Analytics, Therapeutic Care, Population Health Management, Sleep & Respiratory Care and Connected Care Informatics businesses. Personal Health business consists of the Oral Healthcare, Mother & Child Care and Personal Care. Other consists of Innovation, Emerging Businesses, IP Royalties, Central costs and Other. Notably, Philips completed the divestiture of Domestic Appliances business.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $171.396B 18.47
Stryker (SYK) United States $105.786B 29.88
Medtronic (MDT) Ireland $105.197B 15.06
Boston Scientific (BSX) United States $70.544B 28.70
ResMed (RMD) United States $31.368B 35.71
Zimmer Biomet Holdings (ZBH) United States $26.486B 18.40
Baxter (BAX) United States $20.494B 11.58
Bio-Rad Laboratories (BIO) United States $13.968B 33.17
Smith & Nephew SNATS (SNN) United Kingdom $12.105B 0.00
Envista Holdings (NVST) United States $6.408B 20.24
Perrigo (PRGO) Ireland $4.742B 16.96
BellRing Brands (BRBR) United States $4.409B 27.98
Haemonetics (HAE) United States $4.011B 27.32
Owens & Minor (OMI) United States $1.041B 5.66
Warby Parker (WRBY) United States $0.984B 0.00
Zevia PBC (ZVIA) United States $0.253B 0.00
Vapotherm (VAPO) United States $0.027B 0.00